Private Company Edition: Revelation Partners amassed $608m, Bioluminescence Ventures emerged with $477m and Abingworth raised $356m for late-stage programs. In recent financings, MapLight closed a $225m series C round while Triveni launched with $92m and Gate garnered $60m in series A rounds.

The preclinical start-up is identifying allosteric binders that can inhibit or activate metabolic proteins. Atavistik will focus on genetically defined diseases then test its candidates in broader populations.

Taysha gains control of GAN candidate and program; BI licenses COMT inhibitors from Lieber Institute; plus three new gene therapy-driven tie-ups between biopharma and academia.

Deal snapshot: Rodeo’s preclinical work in modulating the 15-PDGH enzyme may yield novel regenerative therapies for inflammation, Amgen says, including GI and post-bone marrow transplant indications.